Additionally, RA-PR058 treatment significantly reduced tau phosphorylation at multiple sites associated with AD pathology, including Ser202/Thr205 (AT8), Thr231 (AT180), and Ser396 in the cortex (Figure 3D–H). This evidence concerns the gene MAPT and Alzheimer disease.